STAR Strides Pharma Science Q4 FY26 results (Jan–Mar 2026) and concall
Strides Pharma delivered strong financial performance in FY26, with a 12% CAGR in revenue and 26% CAGR in EBITDA over the last three years, driven by geographical diversification and improved profitability. While FY26 revenue growth was 6.4% due to a weak U.S. flu season and access market challenges, the company achieved its highest-ever EBITDA margin of 19% and an 18x growth in operational PAT over three years. Investments in R&D and strategic partnerships are expected to drive future growth, particularly in Ex-U.S. markets, with a focus on maintaining strong margins and a resilient balance s
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 9.0%, net profit up 0.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 520 | 551 | 556 | 499 | 522 +0% | 554 +1% | 606 +9% |
| EBITDA | 55 | 74 | 68 | 67 | 62 +13% | 81 +9% | 74 +9% |
| Net profit | 17 | 15 | 16 | 13 | 32 +88% | 122 +713% | 16 +0% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
